Accredited CME/NCPD/CPE Podcasts

Gain valuable insights into the complexities of diagnosing and managing dedifferentiated liposarcoma (DDLPS) and earn free CME credit with our latest podcast. This episode features expert guidance from Dr. Richard F. Riedel of Duke University and Dr. Candace L. Haddox of Dana-Farber Cancer Institute. Delve into the latest on identifying MDM2 and CDK4 amplification, challenges in diagnosing DDLPS, and updates on emerging therapies like CDK4/6 inhibitors and immunotherapies. Learn how a multidisciplinary approach enhances patient outcomes in this rare and aggressive soft tissue sarcoma. Listen now and advance your expertise!

Click here to claim your CME credit: i3health.com/course-information/podcast-ddlps

Diagnosis and Management of Dedifferentiated Liposarcoma: A Multidisciplinary Task Force Podcast

Stay ahead in NSCLC management with this accredited podcast! HER2 alterations, including gene mutations and protein overexpression, are key therapeutic targets, but their complexity can challenge treatment decisions.

In Module 1 of this podcast, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, provides essential insights and testing recommendations to optimize patient care. Listen now!

Click here to claim CME/NCPD credit: https://bit.ly/49NCaQu

What’s New With HER2: Charting New Paths in NSCLC Care Module 1 Podcast: HER2 in NSCLC: Actionable Insights and Testing Recommendations

Stay ahead in NSCLC management with our accredited podccast! HER2 alterations, including gene amplifications, mutations, and protein overexpression, are critical therapeutic targets, but their heterogeneity can complicate treatment strategies.

In Module 2, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, explores advanced testing methodologies and strategies to navigate HER2 complexities and optimize patient outcomes. Listen now!

Click here to claim CME/NCPD credit: https://bit.ly/405xEJO

What’s New With HER2: Charting New Paths in NSCLC Care Module 2 Podcast

Join Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, in Module 1 of this podcast series as she explores the challenges of diagnosing systemic mastocytosis (SM), a rare and often under recognized mast cell disease. 

In this episode, Dr. Castells discusses the wide range of SM symptoms—including anaphylaxis, cutaneous, gastrointestinal, neuropsychiatric, and musculoskeletal manifestations—and offers essential guidance on recognizing the signs, confirming the diagnosis, and improving patient outcomes through early intervention. 

Listen now to enhance your clinical knowledge and be sure to claim your credit after the episode!

Click on the link to claim your credit now: https://bit.ly/3Y3ivHM

Click here to continue listening to Module 2 of this podcast series: https://bit.ly/43VoFNP

Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies - Module 1

Tune in to Module 2 of our podcast series as Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, explores strategies for developing personalized management plans for patients with systemic mastocytosis (SM). This episode covers the latest advancements in treatment, including tyrosine kinase inhibitors (TKIs), supportive care interventions, and practical approaches to tailoring therapies based on disease subtype and symptom burden. Listen now to stay up to date on best practices for improving patient outcomes and quality of life—and don’t forget to claim your credit after the episode!

Click here to claim credit for this activity: https://bit.ly/43VoFNP

Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies - Module 2

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. 

In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now!

Click here to claim you CE credit for this activity: https://bit.ly/45u106o

Click here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care - Module 1

LAST CHANCE – Expires November 21!

Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.

Listen now and earn 0.5 CME credit: bit.ly/49GyP5T

EXPIRING SOON! Diagnosis and Management of Dedifferentiated Liposarcoma

Stay ahead in NSCLC management with this accredited podcast! HER2 alterations, including gene mutations and protein overexpression, are key therapeutic targets, but their complexity can challenge treatment decisions.

In Module 1 of this podcast, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, provides essential insights and testing recommendations to optimize patient care. Listen now!

Click here to claim CME/NCPD credit: bit.ly/49NCaQu

EXPIRING SOON! What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: Actionable Insights and Testing Recommendations

Stay ahead in NSCLC management with our accredited podccast! HER2 alterations, including gene amplifications, mutations, and protein overexpression, are critical therapeutic targets, but their heterogeneity can complicate treatment strategies.

In Module 2, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, explores advanced testing methodologies and strategies to navigate HER2 complexities and optimize patient outcomes. Listen now!

Click here to claim CME/NCPD credit: bit.ly/405xEJO

EXPIRING SOON! What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC

Join Lauren M. Madigan, MD, Associate Professor of Dermatology at the University of Utah, for a sneak peek at our upcoming live webinar, Beyond the Skin: Uncovering Systemic Mastocytosis (SM) in Dermatology Practice. In this short interview, Dr. Madigan shares practical insights on why SM is so often diagnosed late, how skin findings can be a key clue to recognition, and what’s new in the rapidly evolving world of targeted therapies.

The webinar will be offered on two dates. Click the links to register for the date that fits your schedule best!

Tuesday, January 13 at 5:00 pm ET - https://bit.ly/4p7HRil
Monday, February 2 at 7:00 pm ET - https://bit.ly/495gnEd


Discovering Systemic Mastocytosis in Practice: A Webinar Preview With Lauren M. Madigan, MD

Join Lauren M. Madigan, MD, Associate Professor of Dermatology at the University of Utah, for a sneak peek at our upcoming live webinar, Beyond the Skin: Uncovering Systemic Mastocytosis (SM) in Dermatology Practice. In this short interview, Dr. Madigan shares practical insights on why SM is so often diagnosed late, how skin findings can be a key clue to recognition, and what’s new in the rapidly evolving world of targeted therapies.

The webinar will be offered on two dates. Click the links to register for the date that fits your schedule best!

Tuesday, January 13 at 5:00 pm ET - bit.ly/4p7HRil
Monday, February 2 at 7:00 pm ET - bit.ly/495gnEd

Ready to close the gap in HER2-mutant NSCLC care? Join Memorial Sloan Kettering experts Helena A. Yu, MD, and Maria Arcila, MD, for a live webinar on optimizing HER2 testing and integrating the latest targeted therapies into your practice. They’ll walk through how to improve detection and ensure your patients are getting the most effective, up-to-date treatments available.

You can catch the live session on either of these dates:

Wednesday, January 8 at 5:00 pm ET: https://bit.ly/4iZxnA0
Monday, January 26 at 5:00 pm ET: https://bit.ly/4qALw9J

Navigating HER2-Mutant NSCLC Pathology and Management: A Webinar Preview With Helena A. Yu, MD, and Maria Arcila, MD

Ready to close the gap in HER2-mutant NSCLC care? Join Memorial Sloan Kettering experts Helena A. Yu, MD, and Maria Arcila, MD, for a live webinar on optimizing HER2 testing and integrating the latest targeted therapies into your practice. They’ll walk through how to improve detection and ensure your patients are getting the most effective, up-to-date treatments available.

You can catch the live session on either of these dates:

Wednesday, January 8 at 5:00 pm ET: bit.ly/4iZxnA0
Monday, January 26 at 5:00 pm ET: bit.ly/4qALw9J

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care - Module 1

Oncology Data Advisor®

Related tracks